Article
Evolution in understanding of DME suggests new targets, treatment paradigms
While there are extensive data supporting the concept that antiVEGF agents may have a role in the treatment of diabetic macular edema (DME), emerging knowledge about DME pathogenesis is suggesting alternate therapeutic targets and new paradigms for multidrug treatment, said Lloyd P. Aiello, MD, PhD, director, Beetham Eye Institute, Joslin Diabetes Center, Boston.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
